Elevance Health heads into earnings with shorts retreating and Barclays lifting its target

The Street is cautiously bullish but the July earnings print left a mark. Barclays raised its target to $469 this morning, maintaining an Overweight rating, the freshest signal on the tape and a meaningful data point one week before results. Beyond that, most analyst activity clusters around mid-July, when the stock's 12.6% single-day drop prompted a flurry of target revisions in both directions. Firms with positive ratings, including Wells Fargo, TD Cowen, and Truist, trimmed targets but held their constructive views. RBC and Baird marked down targets more conservatively and stayed neutral. The consensus mean target of $451 implies roughly 13% upside to the $400 close, a gap that reflects the uncertainty baked into the stock's recovery path. At a forward PE of around 13.8 and EV/EBITDA of 10.3, valuation multiples have edged lower over the past 30 days even as the stock has broadly held its ground, which keeps the bull case on valuation intact. The forward earnings growth factor ranks in the 89th percentile, a standout figure that anchors the bullish argument around expected profit acceleration into 2026.

The bear case, however, is not trivial. Medicaid margin pressure, a projected shrinkage in Medicaid membership, and concerns around medical cost trends have weighed on managed care broadly. Peers have felt this acutely. CNC gained 3.9% on the week, MOH added 3.1%, and HUM rose 4.5%, suggesting sector sentiment has improved ahead of earnings season rather than deteriorated further. ELV posted a more modest 1.9% gain over the same period, which could mean it has less recovery premium to unwind, or that investors are applying more scrutiny to its specific earnings setup. UNH was roughly flat on the week, up just 0.4%.

CEO Gail Boudreaux bought shares in the open market on July 17, the day after the post-earnings selloff, purchasing roughly 2,725 shares across two transactions at prices near $367 to $368, a combined value just over $1 million. A director also bought 1,000 shares the same day at similar levels. Neither trade was flagged as part of a pre-arranged 10b5-1 plan, which makes the discretionary framing notable. At the current price near $400, those buyers are already sitting on a gain of roughly 9%. BlackRock remains the largest institutional holder with just under 9% of shares, and T. Rowe Price added roughly 228,000 shares in the most recent disclosed period. Wellington Management added nearly 985,000 shares as of July, one of the more meaningful recent accumulation moves among the top holders.

The history of ELV earnings moves sets a high bar for comfort. The July quarter produced a 12.6% drop on the day and an 8.8% decline over the following five days. With the stock having recovered most of that ground to trade back near $400, the question heading into October 14 is whether the company's Q3 medical cost experience and its updated guidance for 2026 will validate that rebound or reprice the stock again.